Work

Utilization of PARP inhibitor maintenance therapy, with or without bevacizumab, in the treatment of patients with homologous recombination proficient, wild-type BRCA1/2 ovarian carcinoma

Year: 2024

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2024.07.629

Authors: Arielle Weiss, Sharon Wu, Jason Conger, Premal Thaker, Thomas Herzog, Matthew Oberley, Gina Mantia-Smaldone

Institutions: Fox Chase Cancer Center, Temple University Hospital, Caris Life Sciences (United States), Washington University in St. Louis, University of Cincinnati

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4403249939

FWCI:

Cites:

Cited by:

Related to: 10